Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Anatara Lifesciences (ANR) receives ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome (IBS) and psychological functioning trials
  • The expansion comes after the company was facing a significant screening failure rate due to the strict eligibility criteria
  • The approval will expand eligibility to all IBS subtypes, as opposed to only the constipation subtype
  • The IBS results will not be influenced by the change, but the psychological functioning study reporting is now expected in early next year
  • Shares are trading in the grey at 6.3 cents each at 2:40 pm AEST

Anatara Lifesciences (ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome (IBS) and psychological functioning trials.

The expansion comes after the company was facing a significant screening failure rate due to the strict eligibility criteria.

The approval will expand eligibility to all IBS subtypes, as opposed to only the constipation subtype.

This allows for 300 potential participants, who previously weren’t able to be enrolled in the trial due to not having diarrhoea predominant IBS.

The psychological functioning trials will now be able to recruit participants from the mild to moderate range of scores on the Depression Anxiety Stress Scale.

ANR said the change is not expected to influence the timeline for the IBS results. However, the psychological functioning study reporting is now expected in early next year, as opposed to late this year.

“The delays have been frustrating for all concerned including our shareholders and these should represent the final modifications,” Chair David Brooks said.

Shares were trading in the grey at 6.3 cents each at 2:40 pm AEST.

ANR by the numbers
More From The Market Herald

" Alara Resources (ASX:AUQ) forms JV to bid for Khnaiguiyah project licence

Alara Resources (ASX:AUQ) has formed a joint venture with Al Tasnim Enterprises to lodge a bid…

" Firefinch (ASX:FFX) under pressure with delays and funding issues flagged at Morila

Firefinch (ASX:FFX) is facing funding issues, insufficient production levels, and delays at the Morila mine in…

" Dimerix’s (ASX:DXB) DMX-700 study shows significant 80pc reduction in lung injury

Dimerix (ASX:DXB) has released its pipeline program DMX-700 study results which indicated a significant 80 per…

" Tesoro Gold (ASX:TSO) confirms El Zorro as a new Chilean Gold District

Tesoro Gold (ASX:TSO) has confirmed its El Zorro project as a new Chilean Intrusive Related Gold…